Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.

The neuraminidase inhibitors (NAIs) are an effective class of antiviral drugs for the treatment of influenza A and B infections. Until recently, only a low prevalence of NAI resistance (<1%) had been detected in circulating viruses. However, surveillance in Europe in late 2007 revealed significant numbers of A(H1N1) influenza strains with a H274Y neuraminidase mutation that were highly resistant to the NAI oseltamivir. We examined 264 A(H1N1) viruses collected in 2008 from South Africa, Oceania and SE Asia for their susceptibility to NAIs oseltamivir, zanamivir and peramivir in a fluorescence-based neuraminidase inhibition assay. Viruses with reduced oseltamivir susceptibility were further analysed by pyrosequencing assay. The frequency of the oseltamivir-resistant H274Y mutant increased significantly after May 2008, resulting in an overall proportion of 64% (168/264) resistance among A(H1N1) strains, although this subtype represented only 11.6% of all isolates received during 2008. H274Y mutant viruses demonstrated on average a 1466-fold reduction in oseltamivir susceptibility and 527-fold reduction in peramivir sensitivity compared to wild-type A(H1N1) viruses. The mutation had no impact on zanamivir susceptibility. Ongoing surveillance is essential to monitor how these strains may spread or persist in the future and to evaluate the effectiveness of treatments against them.

[1]  I. Barr,et al.  Influenza viruses with reduced sensitivity to the neuraminidase inhibitor drugs in untreated young children. , 2008, Communicable diseases intelligence quarterly report.

[2]  A. Nicoll,et al.  Observed oseltamivir resistance in seasonal influenza viruses in Europe interpretation and potential implications. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[3]  I. Barr,et al.  Adamantane resistance in influenza A(H1) viruses increased in 2007 in South East Asia but decreased in Australia and some other countries. , 2008, Antiviral Research.

[4]  V. Gregory,et al.  Widespread Oseltamivir Resistance in Influenza A Viruses (H1N1), South Africa , 2008, Emerging infectious diseases.

[5]  A. Lackenby,et al.  Oseltamivir-Resistant Influenza Viruses A (H1N1), Norway, 2007–08 , 2009, Emerging infectious diseases.

[6]  J. Oxford,et al.  The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. , 2002, Antiviral research.

[7]  Larisa V. Gubareva,et al.  Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008 , 2008, Antimicrobial Agents and Chemotherapy.

[8]  Yoshihiro Kawaoka,et al.  oseltamivir: descriptive study , 2022 .

[9]  A. Monto.  Antivirals and influenza: frequency of resistance. , 2008, The Pediatric infectious disease journal.

[10]  Colin A. Russell,et al.  The Global Circulation of Seasonal Influenza A (H3N2) Viruses , 2008, Science.

[11]  I. Barr,et al.  Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. , 2004, Antiviral research.

[12]  M. Zambon,et al.  Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  Catherine Macken,et al.  Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use , 2006, Antimicrobial Agents and Chemotherapy.

[14]  Laurent Kaiser,et al.  Influenza virus neuraminidase inhibitors , 2000, The Lancet.

[15]  L. Gubareva,et al.  Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. , 2009, Antiviral research.